Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models

N Engl J Med. 2020 Sep 3;383(10):e63. doi: 10.1056/NEJMp2020076. Epub 2020 Jul 1.

Authors

Meagan E Deming¹, Nelson L Michael¹, Merlin Robb¹, Myron S Cohen¹, Kathleen M Neuzil¹

Affiliation

¹ From the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.E.D., K.M.N.), the Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring (N.L.M.), and the Henry Jackson Foundation, Bethesda (M.R.) - all in Maryland; and the Institute for Global Health and Infectious Diseases, School of Medicine, University of North Carolina, Chapel Hill (M.S.C.).

No abstract available

MeSH terms

Betacoronavirus
COVID-19
COVID-19 Vaccines
Coronavirus Infections / prevention & control*
Human Experimentation / ethics
Human Experimentation / standards*
Humans
Pandemics / prevention & control*
Patient Safety
Pneumonia, Viral / prevention & control*
Risk
SARS-CoV-2
Viral Vaccines*

Substances

COVID-19 Vaccines
Viral Vaccines

Grants and funding

T32 AI007524/AI/NIAID NIH HHS/United States